Stable Isotope Labelled Utomilumab Biosimilar – Anti-Human TNFRSF9 mAb – Research Grade

Reference: PX-TA1012-SIL-1MG


Product type


Expression system


Product nameStable Isotope Labelled Utomilumab Biosimilar - Anti-Human TNFRSF9 mAb - Research Grade
SourceDrugBank DB15113
Expression systemMammalian cells
Molecular weightLC: 24kDa
HC: 51kDa
BufferPBS pH7.5
Delivery conditionBlue Ice
Delivery Time3-5 days if in stock; 5-8 weeks if production needed
Storage condition4°C for short term; -20°C for long term
Aliases /SynonymsUtomilumab
Related ProductsPX-P4059
NoteFor research use only. Not suitable for clinical or therapeutic use.
ClonalityMonoclonal Antibody
LabellingArginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99%
Isotopic Enrichment99%
Stability1 year

General information about Utomilumab

Utomilumab is a monoclonal antibody that binds to 4-IBB protein (also known as CD137 protein). 4-IBB protein is a receptor found in different immune cells such as helper T-cells, killer T-cells and natural killer cells. 4-IBB/CD137 protein is a costimulatory receptor whose activation results in a series of events that leads to cytokine secretion and effector functions. Hence, targeting CD137 protein has been linked to antitumor immunity response and overall tumor reduction. Indeed, once utomilumab is injected in the bloodstream its specific binding to CD137 protein stimulates the immune cells which, as a result, enhances the immune response against tumors.
Utomilumab is under investigation as a potential treatment for advanced forms of cancer either alone or in combination with other therapies. Indeed, pre-clinical studies have suggested that the combination of utomilumab with a checkpoint inhibitor such as anti-PD1/anti-PDL1, or other immunotherapies may lead to amplified immune response. This demonstrates utomilumab anti-tumor activity.
Phase 1 study evaluated the outcome of administering utomilumab in combination with rituximab in patients with certain type of non-Hodgkin’s lymphoma (NHL) also known as CD20-positive NHL. Phase I clinical trial results further confirmed the anti-tumor activity of utomilumab. The utomilumab administration with rituximab was well tolerated and none of the patients interrupted the treatment because of treatment-related side effects. No dose-related toxicities were recorded. The safety and anti-tumor activity of this antibody-based therapy was assessed in phase 1b clinical trial. Utomilumab was tested in combination with pembrolizumab for different advanced solid tumors including renal cell carcinoma, head and neck cancer, thyroid cancer, pancreatic cancer, non-small cell lung cancer, small cell lung cancer, colon cancer, sarcoma, thymoma and melanoma. Result showed that the administration of utomilumab together with pembrolizumab to patients with solid tumors was safe. Once again, no toxicity was observed with increased doses of utomilumab. This product is for research use only.


There are no reviews yet.


Be the first to review “Stable Isotope Labelled Utomilumab Biosimilar – Anti-Human TNFRSF9 mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Contact us

Send us a message from the form below

    Cart (0 Items)

    Your cart is currently empty.

    View Products